|
1
|
Regulation of p53 by TopBP1: a potential mechanism for p53 inactivation in cancer.
|
Mol Cell Biol
|
2009
|
1.28
|
|
2
|
Non-Hodgkin's lymphomas, version 1.2013.
|
J Natl Compr Canc Netw
|
2013
|
1.20
|
|
3
|
14-3-3Tau regulates ubiquitin-independent proteasomal degradation of p21, a novel mechanism of p21 downregulation in breast cancer.
|
Mol Cell Biol
|
2010
|
1.06
|
|
4
|
Non-Hodgkin's lymphomas.
|
J Natl Compr Canc Netw
|
2011
|
1.06
|
|
5
|
Constitutively decreased TGFBR1 allelic expression is a common finding in colorectal cancer and is associated with three TGFBR1 SNPs.
|
J Exp Clin Cancer Res
|
2010
|
1.05
|
|
6
|
Non-Hodgkin's Lymphomas, version 3.2012.
|
J Natl Compr Canc Netw
|
2012
|
1.03
|
|
7
|
Strategies to enhance patient adherence: making it simple.
|
MedGenMed
|
2005
|
0.96
|
|
8
|
Non-Hodgkin's lymphomas, version 2.2014.
|
J Natl Compr Canc Netw
|
2014
|
0.94
|
|
9
|
Acute lymphoblastic leukemia.
|
J Natl Compr Canc Netw
|
2012
|
0.93
|
|
10
|
Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.
|
Invest New Drugs
|
2014
|
0.77
|
|
11
|
Disseminated fusariosis during acute myelogenous leukemia induction treatment.
|
Blood
|
2014
|
0.75
|